Hypoalbuminemia in the Outcome of Patients with Non-variceal Upper Gastrointestinal Bleeding
Overview
Authors
Affiliations
Introduction And Aim: The role of serum albumin level in patients with non-variceal upper gastrointestinal bleeding (NVUGB) has not been extensively studied. Our aim was to evaluate the role of serum albumin on admission in terms of in-hospital mortality in patients with NVUGB.
Materials And Methods: Patients admitted with NVUGB during a 4-year period were prospectively included. Demographic, clinical, and laboratory data were collected. ROC curve analysis was used to determine the cutoff value for serum albumin on admission that made a distinction between deceased patients and survivors with respect to serum albumin on admission, as well as its overall performance compared with the Rockall score.
Results: 185 patients with NVUGB were evaluated. Men predominated (56.7%) and a mean age of 59.1±19.9 years was found. Mean serum albumin on admission was 2.9±0.9g/dl with hypoalbuminemia (< 3.5g/dl) detected on admission in 71.4% of cases. The ROC curve found that the best value for predicting hospital mortality was an albumin level of 3.1g/dl (AUROC 0.738). Mortality in patients with albumin ≥ 3.2g/dl was 1.2% compared with 11.2% in patients with albumin<3.2g/dl (P=.009; OR 9.7, 95%CI 1.2-76.5). There was no difference in overall performance between the albumin level (AUORC 0.738) and the Rockall score (AUROC 0.715) for identifying mortality.
Conclusions: Patients with hypoalbuminemia presenting with NVUGB have a greater in-hospital mortality rate. The serum albumin level and the Rockall score perform equally in regard to identifying the mortality rate.
Choi J, Lee J, Lee S, Kim Y, Lee Y, Kim T Gastroenterol Res Pract. 2022; 2022:1172540.
PMID: 36275426 PMC: 9584709. DOI: 10.1155/2022/1172540.
Seo J, Kim Y, Lee Y, Chung H, Kim T BMC Emerg Med. 2022; 22(1):135.
PMID: 35879671 PMC: 9311345. DOI: 10.1186/s12873-022-00696-4.
Research Progress and Treatment Status of Liver Cirrhosis with Hypoproteinemia.
Wen J, Chen X, Wei S, Ma X, Zhao Y Evid Based Complement Alternat Med. 2022; 2022:2245491.
PMID: 35251204 PMC: 8893996. DOI: 10.1155/2022/2245491.
Chen L, Zheng H, Wang S PeerJ. 2021; 9:e11656.
PMID: 34221734 PMC: 8236237. DOI: 10.7717/peerj.11656.
Koushki M, Farrokhi Yekta R, Amiri-Dashatan N, Dadpay M, Goshadrou F BMC Complement Altern Med. 2019; 19(1):205.
PMID: 31391093 PMC: 6686504. DOI: 10.1186/s12906-019-2623-4.